Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands

The recent EMPA-KIDNEY trial showed evidence for preventing disease progression in adult patients with chronic kidney disease (CKD) treated with empagliflozin. It is however yet unknown if use of empagliflozin is cost effective in the Netherlands. We aimed to evaluate the cost effectiveness of empag...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2024-12, Vol.19 (12), p.e0315509
Hauptverfasser:	Slob, Bart, Fens, Tanja, Weersma, Maaike, Postma, Maarten, Boersma, Cornelis, de Jong, Lisa
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adults Aged Analysis Antidiabetics Benzhydryl Compounds - economics Benzhydryl Compounds - therapeutic use Biology and Life Sciences Body mass index Cardiovascular disease Chronic kidney failure Cost analysis Cost benefit analysis Cost effectiveness Cost-Effectiveness Analysis Creatinine Development and progression Diabetes Diabetes mellitus Disease prevention Disease Progression Drug therapy Economic aspects Economics Evidence (Law) Female Glucosides - economics Glucosides - therapeutic use Health aspects Health care expenditures Heart failure Hemodialysis Humans Hypertension Impact analysis Kidney diseases Kidneys Male Markov Chains Medicine and Health Sciences Middle Aged Mortality Netherlands Parameter sensitivity Parameter uncertainty Patients People and places Peritoneal dialysis Pharmacology Quality of life Quality-Adjusted Life Years Renal Insufficiency, Chronic - drug therapy Renal Insufficiency, Chronic - economics Sensitivity analysis Social Sciences Sodium-Glucose Transporter 2 Inhibitors - economics Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Transplants & implants Type 2 diabetes Uncertainty analysis United Kingdom Urine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The recent EMPA-KIDNEY trial showed evidence for preventing disease progression in adult patients with chronic kidney disease (CKD) treated with empagliflozin. It is however yet unknown if use of empagliflozin is cost effective in the Netherlands. We aimed to evaluate the cost effectiveness of empagliflozin in adult patients with CKD in the Netherlands. A cost-effectiveness analysis was conducted using a Markov state microsimulation model, simulating kidney progression of CKD patients with eGFR
ISSN:	1932-6203 1932-6203
DOI:	10.1371/journal.pone.0315509